INTRODUCTION
Ferroquine (FQ; SSR 97193) is a new 4-aminoquinoline organometallic chloroquine (CQ) analog that is being developed for the curative treatment of adults and children with uncomplicated malaria caused by Plasmodium falciparum , likely in multi-drug regimens with an artemisinin. In vitro data indicate that FQ is active against CQ-resistant and CQ-sensitive P. falciparum strains and against P. vivax . 1 An increasing number of reports describe in vitro growth inhibitory capability of FQ against CQ-resistant and CQ-sensitive P. falciparum laboratory strains, often superior to CQ. [2] [3] [4] [5] [6] [7] [8] As clinical trials of FQ proceed in support of licensure, additional in vitro testing of P. falciparum field isolates, especially those obtained from sites of FQ efficacy trials with known CQ-resistant P. falciparum , may improve understanding of the capabilities of FQ. In Kenya, where drug resistance often emerges in eastern Africa, P. falciparum remains largely resistant to CQ, which suggests a useful location to obtain isolates for in vitro testing. [9] [10] [11] The aim of this study was to assess the inhibitory activity of CQ versus FQ against P. falciparum field isolates obtained in western Kenya, a region where CQ resistance is well established. To do this assessment, immediate ex vivo (IEV) or culture-adapted P. falciparum field isolates were examined in vitro by using a SYBR Green I 50% inhibitory concentration (IC 50 ) drug sensitivity assay. Additionally, we assessed P. falciparum field isolates for drug resistance markers ( P. falciparum multidrug resistance 1 [ Pfmdr1 ] gene and P. falciparum chloroquine resistance transporter [ Pfcrt ]) gene to find associations with IC 50 values. 12 Persons attending outpatient clinics in 2009-2010 who were ≥ 6 months of age and had suspected uncomplicated P. falciparum malaria were invited to participate in the study. Written informed consent was obtained from all participants or guardians. Anyone treated for malaria within the past one month was ineligible.
MATERIALS AND METHODS

Protocol
Sample collection and preparation. Blood samples (2-3 mL) were obtained from persons who consented and had a positive P. falciparum rapid diagnostic test (RDT) (Parascreen; Zephyr Biomedicals, Verna Goa, India) and transported to the laboratory. Three blood spots (each approximately 100 μL) were placed on FTA filter paper (Whatman Inc., Bound Brook, NJ) for parasite DNA extraction and molecular analysis. Malaria blood films on glass slides were made for staining with Giemsa in the laboratory for microscopic examination to confirm RDT results and determine parasitemia. For discrepancies between RDT and microscopy results, microscopic results were used as final results.
Plasmodium falciparum -infected blood specimens from Kisumu District Hospital (< a 15 minute drive to the laboratory) were collected in acid citrate dextrose vacutainer tubes (Becton-Dickinson, Franklin Lakes, NJ) and transported within four hours for IEV processing. Plasmodium falciparum-infected blood specimens from Kericho and Kisii District Hospitals (2-hour drives to the laboratory) were placed in storage-transport medium and refrigerated at 4°C until transported to the laboratory, generally within 72 hours, for culture-adaptation.
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In vitro IC 50 drug testing. A SYBR Green I-based in vitro IC 50 drug sensitivity assay was used to test each P. falciparum field isolate against CQ and FQ. [13] [14] [15] [16] Ferroquine was provided by Sanofi-Aventis Corporation (Paris, France), and CQ was provided by the Walter Reed Army Institute of Research (Silver Spring, MD).
Plasmodium falciparum laboratory reference clones assayed periodically for internal controls against both drugs included D6, classified as CQ sensitive, and W2, classified as CQ resistant. 17 Clones D6 and W2 were obtained from frozen stocks and culture-adapted for SYBR Green I assays.
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Stock drug solutions at concentrations of 1 mg/mL were prepared. Ferroquine was dissolved in absolute ethanol, and CQ was dissolved in 1.5 mL of de-ionized water and 3.5 mL of absolute ethanol. Further dilutions were in complete RPMI 1640 medium to the desired starting concentration, followed by serial two-fold dilutions to generate 10 concentrations across the plates. Dilution ranges were as follows: CQ (3,125-6 nM) and FQ (2,305-4.5 nM). Pre-diluted drug plates were prepared fresh and used immediately or stored at -80°C for not longer than one month before use.
Plasmodium falciparum isolates processed IEV were assayed without culture adaptation. 16 Blood samples with > 1% parasitemias were adjusted to 1% parasitemias at 2% hematocrits, and those with ≤ 1% parasitemias were used unadjusted at 2% hematocrits. For IEV and culture-adapted assays, transfer of parasite samples and drug aliquots onto microculture plates and IC 50 values depicted by the SYBR Green I drug assay were as described. 16 Plasmodium falciparum field isolates obtained from two sites were culture adapted before assay. The isolates were cultured at a 6% hematocrit to establish parasite replication robustness, reaching 3-8% parasitemia within 7-30 days. 16, 17 For IC 50 drug assays, P. falciparum aliquots were adjusted to a 2% hematocrit and a 1% parasitemia.
Molecular analyses of P. falciparum field isolates and reference clones. Plasmodium falciparum field isolate DNA for all molecular assays was extracted from FTA filter paper samples or whole blood by using the QIAamp DNA Blood Mini Kit (QIAGEN, Valencia, CA) according to manufacturer's instructions. Genomic DNA from laboratory clones used as controls was extracted in similar fashion.
A single nucleotide polymorphism (SNP), K76T, in the Pfcrt gene, which is well described in Kenya in conferring CQ resistance, was determined as described. 10 For Pfmdr1 , an estimated copy number was determined by using a 2 −ΔΔCt method of relative quantification. 18 For the calibrator, we used P. falciparum reference clone 3D7 genomic DNA that contained one copy of Pfmdr1 . Plasmodium falciparum tubulin was used as a housekeeping gene, and Dd2 laboratory reference clone DNA was used as a Pfmdr1 multiple gene copy control. The SNP analysis for Pfmdr1 codons 86, 184, 1034, and 1042 was conducted as described 19, 20 by using a real-time, mutation-specific polymerase chain reaction.
Statistical analyses. Data were analyzed by using nonparametric Kruskal-Wallis one-way analysis of variance by ranks, the Mann-Whitney U test, Dunn's multiple comparison test, and Pearson product-moment correlation coefficient (GraphPad Prism 4.00 for Windows; GraphPad Software, San Diego, CA, and Sigma Plot version 10; Systat Software, Inc., San Jose, CA).
RESULTS
SYBR Green I IC 50 drug assays. We collected 146 P. falciparum field isolates and assayed 88 IEV and 58 as cultureadapted against CQ and FQ by using an SYBR Green I assay. A successful assay result was defined as a dose-response relationship across the 10 drug dilutions, for one or both drugs, per field isolate.
Individual and median IC 50 values (nM) for IEV and culture-adapted P. falciparum field isolates against CQ and FQ and P. falciparum laboratory reference clones D6 (CQ sensitive) and W2 (CQ resistant) are shown in Figure 1 . Median IC 50 values for CQ were consistently higher than those for FQ for IEV and culture-adapted isolates. For CQ IC 50 ,values, 17 (21%) of 81 IEV and 12 (21%) of 58 culture-adapted P. falciparum isolates had values > 141 nM, which is a previously established discriminative IC 50 breakpoint value indicative of CQ resistance. 10 For FQ, there is no discriminative IC 50 value breakpoint indicative of resistance. We observed no difference between FQ median IC 50 values for IEV or culture-adapted isolates versus those of D6 CQ-sensitive and W2 CQ-resistant laboratory reference clones ( P > 0.05).
A Pearson correlation coefficient analysis of CQ and FQ IC 50 values was performed for IEV and culture-adapted isolates. The r values of -0.001178 and -0.0596 for IEV and culture-adapted isolates, respectively, are shown in Figure 2 . These values indicated a lack of correlation (cross-resistance) between CQ and FQ in vitro activity.
For P. falciparum reference clones D6 (CQ sensitive) and W2 (CQ resistant), the median CQ IC 50 value for each clone was greater than that for FQ ( P ≤ 0.05). The CQ IC 50 median value against W2 was higher than the 141 nM breakpoint value.
Molecular assays of P. falciparum field isolates and laboratory reference clones. The Pfcrt mutation 76T, which is present in > 80% (87 of 108) of P. falciparum field isolates, conferred higher median IC 50 values for CQ, but not for FQ, in comparison with Pfcrt wild type K76 ( Figure 3A and B) . For FQ, the Pfcrt genotype had little effect on median IC 50 values ( Figure 3B ). Among all P. falciparum field isolates expressing Pfcrt mutation 76T, the median IC 50 value for CQ was higher than that for FQ ( P < 0.05, by Mann-Whitney U test). As in earlier work, mixed (wild type plus mutant) and mutant Pfcrt K76T genotypes were combined in some analyses to express a total mutant population. 10, 16 The Pfmdr1 gene was not amplified in P. falciparum field isolates when quantified relative to P. falciparum reference clones 3D7 (mean = 1 copy) and multiple-drug resistant Dd2 (mean = 3 copies) ( Figure 4A ). The proportions of Pfmdr1 codon SNPs were highest at codon 86 (33%). There were far fewer at codons 184 and 1034 and none at codon 1042, regardless of collection site. The Pfmdr1 codon 86 genotype (wild type versus mutant) expressed in P. falciparum field isolates had little effect on CQ or FQ median IC 50 values ( Figure 4B ).
DISCUSSION
In a direct comparison of antimalarial activities of CQ and FQ by using an SYBR Green I in vitro assay, we found that FQ was consistently more potent than CQ against P. falciparum field isolates obtained in western Kenya, a region to which CQ-resistant P. falciparum is endemic. Moreover, FQ showed higher potency than CQ against the well-characterized CQ-resistant P. falciparum laboratory clone W2. As expected, most P. falciparum field isolates expressed the Pfcrt mutation (76T), which conferred higher median IC 50 values for CQ but, notably, not for FQ. Our results indicate that FQ should be used to treat persons with P. falciparum malaria, even persons infected with CQ-resistant strains.
Superior in vitro activity of FQ than of CQ has been reported. [21] [22] [23] Our study extends observations of FQ superiority against recently collected CQ-resistant P. falciparum field isolates and the CQ-resistant P. falciparum laboratory reference clone W2. The superiority of FQ was evident in field isolates processed IEV or by culture adaptation. The immediate ex vivo procedure is a simpler and faster technique that in comparison with culture adaptation, reduces cold storage and processing steps of P. falciparum isolates and may reduce clonal selection. 13, 24 Median CQ IC 50 values in the SYBR Green I assay for culture-adapted and IEV samples generally paralleled our earlier 3 H-hypoxanthine uptake findings in culture-adapted P. falciparum isolates from Kenya. 10 For example, approximately 21% of CQ IC 50 values determined by SYBR Green I assay exceeded a previously established discriminative value of 141 nM, and CQ IC 50 value ranges for the P. falciparum laboratory reference clones D6 and W2 were in accordance with established CQ sensitivity profiles. 10 We suggest that these data, especially because there is no in vitro discriminative resistance value for FQ resistance, can be used as a modest baseline from which to track and compare FQ IC 50 values, especially in eastern Africa.
When CQ and FQ IC 50 values for P. falciparum field isolates were plotted against those for specific Pfcrt genotypes, we found a direct relationship with CQ (higher median IC 50 value with Pfcrt mutation 76T) and an inverse relationship with FQ (lower median IC 50 value with Pfcrt wild-type gene K76). The former result was expected, given the known prevalence of Pfcrt 76T in P. falciparum isolates in Kenya. The latter result suggested that Pfcrt 76T has a minimal effect on FQ activity. 5 Ferroquine, which is an organo-metallic complex, differs from CQ in diverse ways, including lipophilicity, shape, volume, and electronic profile. 22, 23 These differences facilitate FQ entry into the P. falciparum vacuoles and, as some investigators propose, prevent FQ extrusion conferred by the Pfcrt 76T mutation, which characterizes CQ-resistant strains. 5, 6 , 21 The ferrocene moiety may confer some of the properties of FQ. 25 In parallel with these earlier findings, our study found no association between IC 50 values for CQ and FQ, which suggested no crossresistance.
The Pfmdr1 gene confers multiple drug resistance when more than one copy is present and is common in Southeast Asia. 26 As expected, Kenya P. falciparum field isolates showed no amplification of the Pfmdr1 gene, which is consistent with findings for the wild type, and are not necessarily associated with multi-drug resistance capability. 27, 28 This finding precluded comment on a role of the Pfmdr1 gene copy number on FQ activity. The Pfmdr1 codon 86 genotype had relatively little effect on CQ and FQ IC 50 values. 7, 8 Nonetheless, it may be useful to track FQ IC 50 values versus Pfmdr1 codon 86 genotypes because P. falciparum FQ resistance markers are not fully identified. 
